Anzeige
Meldung des Tages: Mit Graphen gegen jede Abwehr — Die Zukunft der Drohnen ist da

Roche Holding News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
406,30 $
-12,86 $
-3,07%
346,65 € 01.05.26
Depot/Watchlist
Marktkapitalisierung *
250,27 Mrd. €
Streubesitz
17,13%
KGV
25,93
Dividende
10,22 EUR
Dividendenrendite
2,93%
Nachhaltigkeits-Score
60 %
Index-Zuordnung
-

Roche Holding News

19.09.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
Lunsumio provides high and long-​lasting response rates, with approximately two-​thirds of patients with a complete response in remission after four years 1 Subcutaneous ...
18.09.25 - GlobeNewswire
Roche enters into a definitive merger agreement to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH
89bio’s pegozafermin allows for a potentially best-​in-disease treatment for moderate to severe Metabolic Dysfunction-​Associated Steatohepatitis (MASH), one of the most prevalent ...
05.09.25 - GlobeNewswire
New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
In AVONELLE-​X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study ...
04.09.25 - GlobeNewswire
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union 1 New seven-​year data ...
30.08.25 - GlobeNewswire
Roche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertension
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KARDIA-3 study, presented ...
25.08.25 - GlobeNewswire
Roche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D. The facility will create more than 1,900 jobs and support the ...
01.08.25 - GlobeNewswire
Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)
Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60 With two ...
28.07.25 - GlobeNewswire
Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC
Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E ...
25.07.25 - GlobeNewswire
Roche provides regulatory update on Elevidys™ gene therapy for Duchenne muscular dystrophy in the EU
EMA’s CHMP issued an opinion not to recommend Elevidys™ (delandistrogene moxeparvovec) for the treatment of ambulatory individuals with Duchenne muscular dystrophy (DMD) ...
24.07.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum with 7% growth (CER) in the first half of 2025
Basel, 24 July 2025
24.07.25 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starkes Wachstum im ersten Halbjahr 2025 fort: Verkäufe steigen um 7% (CER)
Basel, 24. Juli 2025
23.07.25 - GlobeNewswire
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer’s disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology. The minimally invasive, blood-​based test can ...
23.07.25 - GlobeNewswire
European Commission approves Roche’s Itovebi for people with ER-positive, HER2-negative, advanced breast cancer with a PIK3CA mutation
Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-​free survival compared with palbociclib and fulvestrant alone 1 ...
22.07.25 - GlobeNewswire
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-​voting equity securities (Genussscheine). Reduction of the nominal ...
22.07.25 - GlobeNewswire
Roche Verwaltungsrat schlägt Umtausch von Genussscheinen in Partizipationsscheine vor
Partizipationsscheine mit einem Nennwert von je CHF 0.001 ersetzen die Genussscheine. Herabsetzung des Nennwerts der Inhaberaktien von CHF 1.00 auf CHF 0.001 je Aktie, zur ...
21.07.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was ...
07.07.25 - PR Newswire
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs PR Newswire
30.06.25 - GlobeNewswire
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 30 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche Pharma Research and Early ...
23.06.25 - GlobeNewswire
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show NXT007 achieved no bleeds requiring treatment in the ...
20.06.25 - GlobeNewswire
Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-​free survival - three times longer than R-GemOx 1 This well-​tolerated investigational combination ...

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »